Developing inhibitors for IDH-mutant astrocytoma with worse therapy response driven by Interleukin-4 Induced 1 (IL4I1)

Dr. Ahmed Sadik

Dennis Friedel

German Cancer Research Center, Heidelberg
University Hospital Heidelberg

Project Summary:
Tumor cells, like any other cell, consume different types of nutrients. However, they come up with new ways to use these nutrients to become more aggressive. In the case of IDH mutant astrocytoma, the tumor cells are using amino acids to suppress the immune system from fighting it. We used artificial intelligence to identify a key protein that the tumor cells use to defeat our immune system. We are developing drugs to deprive the tumor cells from using this protein. We aim in this project to select the more effective drug inhibitors of this protein, and identify the IDH mutant astrocytoma patients who will benefit the most from applying this therapeutic strategy.

Expected Project Timeframe: September 2025 to August 2027

OA PD Dr. med. David Reuss

Prof. Dr. Christiane Opitz